Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Comments on FDA Plausible Mechanism Draft Guidance
-
Letter of Support for FY2027 Funding for NBS Programs
-
Sign-on Letter Urging Reinstatement of the ACHDNC
-
Stakeholder Letter Supporting Joint Resolutions to Overturn FDA Rule on LDTs
-
ACMG Response to Senate HELP Committee RFI on Diagnostics Regulation
-
ACMG Response to RFI on Gene Therapies Access for Rare Diseases
-
Coalition Letter for NBS Funding in FY 2024 Appropriations
-
Amicus Brief for Kanuszewski v MDHHS (6th Circuit) – Newborn Screening Dried Blood Spot
-
ACMG Comments on FDA Proposed Rule for Regulation of LDTs
-
Stakeholder Letter Asking Congress Renew Efforts on CLIA Reform and Urge FDA to Halt LDT Rulemaking